Table 2.
Final body, heart weights, and circulatory levels of free fatty acids (FFAs)creatinine kinase-MB (CK-MB) and Troponin-I (Tn-I) in all groups of rats.
| HFD + ASX + EX-527 | HFD + ASX | HFD | Control + ASX | Control | Parameter |
|---|---|---|---|---|---|
| 531 ± 27ab | 519 ± 29ab | 529 ± 35ab | 429 ± 31 | 437 ± 28 | Final body weight (g) |
| 1.59 ± 0.17abd | 1.28 ± 0.19c | 1.65 ± 0.12 ab | 1.18 ± 0.21 | 1.21 ± 0.18 | Heart weights (g) |
| 311 ± 0.19ab | 2.56 ± 0.27c | 3.23 ± 0.23ab | 2.78 ± 0.25 | 2.71 ± 0.21 | Heart/BW ratio (×10−3) |
| 178.4 ± 11.5ab | 184 ± 8.6ab | 187 ± 12.5ab | 110 ± 10.1 | 105 ± 9.4 | Fasting plasma glucose (mg/dl) |
| 5.2 ± 0.67ab | 5.3 ± 0.61ab | 5.6 ± 0.55ab | 3.3 ± 0.54 | 3.1 ± 0.48 | Fasting plasma insulin (ng/ml) |
| 848 ± 38.2ab | 867 ± 41.5ab | 882 ± 51.1ab | 328 ± 26.3 | 318 ± 22.5 | Serum FFAs (µM) |
| 456 ± 27.9abd | 256 ± 31.1abc | 428 ± 24.9ab | 219 ± 22.1 | 212 ± 17.5 | Serum CK-MB (pg/ml) |
| 385 ± 18.6abd | 178 ± 16.9abc | 391 ± 24.1ab | 153 ± 13.1 | 143 ± 11.5 | Serum Tn-I (pg/ml) |
Data were analyzed for n = 10 samples/group and were significantly different p < 0.05. a: vs. the control rats; b: vs. the control + ASX-treated rats; c: vs. HFD-fed rats, d: vs. HFD + ASX-treated rats. EX-527: a selective SIRT1 inhibitor.